The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | Insights into the management of MDS/MPN overlap syndromes & advice for clinicians
Eric Padron, MD, Moffitt Cancer Center, Tampa, FL, discusses the current approach to managing myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes, which focuses on symptom-directed therapy. He highlights ongoing research aimed at identifying when asymptomatic patients should be treated to prevent disease progression and improve quality and longevity of life. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
